**Core Concept**
CTL (Cytotoxic T Lymphocyte) inducing vaccines are designed to stimulate a specific immune response by activating T cells, which are essential for cell-mediated immunity. Recombinant adeno-associated virus (rAAV) and modified vaccinia Ankara (MVA) are viral vectors used to deliver antigenic peptides to host cells, thereby inducing an immune response.

**Why the Correct Answer is Right**
Recombinant adeno-associated virus (rAAV) and modified vaccinia Ankara (MVA) are being developed as vaccine vectors because they can efficiently deliver genetic material to host cells, inducing a strong immune response. Specifically, rAAV vectors can infect cells and express the encoded antigen, while MVA is a weakened form of the cowpox virus that can also express the antigen, thereby stimulating an immune response. This targeted approach is particularly useful for inducing CTL responses, which are crucial for controlling viral infections.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is not provided, so we'll skip to the next one.
**Option B:** This option is also not provided, so we'll move on.
**Option C:** This option is not correct because while live attenuated vaccines can induce a strong immune response, they are not typically used in combination with rAAV or MVA vectors.
**Option D:** This option is not correct because inactivated vaccines, such as those made from killed or inactivated pathogens, may not induce a strong CTL response.

**Clinical Pearl / High-Yield Fact**
When developing vaccines, it's essential to consider the type of immune response desired. CTL-inducing vaccines, like those using rAAV and MVA vectors, are particularly useful for controlling viral infections and cancer.

**Correct Answer: C.**